Humanized anti-CD19 antibodies
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Sep 19, 2006
Grant Date -
Mar 31, 2005
app pub date -
Aug 2, 2004
filing date -
Jul 31, 2003
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully